Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 1, 2015, Pages 245-251

  Zuo, Chaohui ^a,c   Xia, Man ^a,c   Liu, Jingshi ^a   Qiu, Xiaoxin ^a   Lei, Xiong ^b   Xu, Ruocai ^a   Liu, Hanchun ^a   Li, Jianliang ^a   Li, Yongguo ^b   Li, Qinglong ^b   Xiao, Hua ^a   Hong, Yuan ^a   Wang, Xiaohong ^a   Zhu, Haizhen ^a   Wu, Qunfeng ^c   Burns, Michael ^c   Liu, Chen ^c  

^a HUNAN CANCER HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Combined treatment; Disease free survival; HCC; Hepatitis B virus; Interferon ; Overall survival; TACE

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CISPLATIN; ETHIODIZED OIL; FLUOROURACIL; MITOMYCIN;

ADULT; ADVERSE EFFECTS; AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION; DISEASE FREE SURVIVAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; RETROSPECTIVE STUDY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ETHIODIZED OIL; FEMALE; FLUOROURACIL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84924274917     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.1.245     Document Type: Article

References (38)

1. Breunig IM, Shaya FT, Hanna N, et al (2013). Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. Value Health, 16, 760-8.
2. Chun YH, Kim SU, Park JY, et al (2011). Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer, 47, 2568-75.
3. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. In J Cancer, 127, 2893-917.
4. Fan ST, Mau Lo C, Poon RT, et al (2011). Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg, 253, 745-58.
5. Fina RS (2012). Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition. Liver Cancer, 1, 247-56.
6. Herzer K, Hofmann TG, Teufel A, et al (2009). IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independenity of p53. Cancer Res, 69, 855-62.
7. Hu L, Xue F, Li Y, et al (2014). A long-term follow-up and comprehensive observation of risk and prognosis factors of recurrence and survival after resection of hepatocellular carcinoma. Cell Biochem Biophys, 69, 421-31.
8. Huang G, Lai EC, Lau WY, et al (2013). Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg, 257, 490-505.
9. Hou J, Zhou Y, Zheng Y, et al (2014). Hepatic RIG-I predicts survival and interferon-a therapeutic response in hepatocellular carcinoma. Cancer Cell, 25, 49-63.
10. Ippolito D, Bonaffini PA, Ratti L, et al (2010). Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor. World J Gastroenterol, 16, 5993-6000.
11. Jemal A, Brany F, Center MM, et al (2011). Global cancer statistitics. CA Cancer J Clin, 61, 69-90.
12. Jiang W, Zhang C, Tian Z, et al (2013). hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function. Gene Ther, 20, 1062-9.
13. Jianyong L, Jinjing Z, Wentao W, et al (2014). Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: a single center analysis. Ann Hepatol, 13, 394-402.
14. Ji J, Shi J, Budhu A, et al (2009). MicroRNA expression, survival, and response to interferon in liver cancer. N Eng J Med, 361, 1437-47.
15. Kurth T, Walker AM, Glynn RJ, et al (2006). Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol, 163, 262-70.
16. Kim KM, Kim JH, Park IS, et al (2009). Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol, 24, 806-14.
17. Kumamoto T, TanakaK, Matsuo K, et al (2013). Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report. Anticancer Res, 33, 5585-90.
18. Lin S, Hoffmann K, Schemmer P (2012). Treatment of hepatocellular carcinoma review. Liver Cancer, 1, 144-58.
19. Li KW, Li X, Wen TF, et al (2013). The effect of postoperative TACE on prognosis of HCC: an update. Hepatogastroenterology, 60, 248-51.
20. Li H, Hu Y, Li N, Zhou Y (2012). Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses. Asian Pac J Cancer Prev, 13, 1589-93.
21. Lamm D, Brausi M, O'Donnell MA, et al (2014). Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol, 32, 35.e21-30.
22. Lai CL, Yuen MF (2013). Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology, 57, 399-408.
23. Li F, Guo Z, Zhang Y, et al (2014). Postoperative adjuvant arterial chemoembolization improves the survival of hepatitis B virus-related hepatocellular carcinoma: a retrospective control study. Ir J Med Sci, 183, 688-90.
24. Lencioni R (2012). New progress of non-surgical treatments for hepatocellular carcinoma. Semin Oncol, 39, 503-9.
25. Lin LY, Wong VW, Zhou HJ, et al (2010). Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. J Med Virol, 82, 1495-500.
26. Martin R, Geller D, Espat J, et al (2012). Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review. Hepatogastroenterology, 59, 255-60.
27. Nagano H, Sakon M, Eguchi H, et al (2007). Hepatic resection followed by IFN-a and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology, 54, 172-9.
28. Poortahmasebi V, Alavian SM, Keyvani H, et al (2014). Hepatic steatosis: prevalence and host/viral risk factors in Iranian patients with chronic hepatitis B infection. Asian Pac J Cancer Prev, 15, 3879-84.
29. Qu LS, Jin F, Huang XW, et al (2010). Interferon-α therapy after Curative resection prevents early recurrence and improves survival in patients with hepatitics B virus-related hepatocellular carcinoma. J Surg Oncol, 102, 796-801.
30. Shen Y, Lin ZZ, Hsu CH, et al (2013). Clinical trials in Hepatocellular carcinoma: An update. Liver Cancer, 2, 345-64.
31. Sun P, Yang X, He RQ, et al (2013). Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials. Hepatol Res, 44, 259-69.
32. Sun HC, Tang ZY, Wan L, et al (2006). Postoperative interferon-α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol, 132, 458-65.
33. Sakon M, Nagano H, Dono K, et al (2002). Combination intraarterial 5-Fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer, 2002, 94, 435-42.
34. Tang ZM, Sun BC (2013). Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. World J Gastroenterol, 19, 8895-901.
35. Tanaka K, Yabushita Y, Nakagawa K, et al (2013). Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. Eur J Surg Oncol, 39, 1364-70.
36. Xi T, Lai EC, Min AR, et al (2012). Adjuvant transatheter arterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study. Hepatogastroenterology, 59, 1198-203.
37. Zhong JH, Li LQ (2010). Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res, 40, 943-53.
38. Zhou YM, Zhang XF, Li B, et al (2014). Prognosis after resection of hepatitis B virus-related hepatocellular carcinoma originating from non-cirrhotic liver. Ann Surg, 21, 2406-12.